A UNIQUELY VERSATILE PLATFORM

A UNIQUELY VERSATILE THERAPEUTIC TOOL COMBINING THE POWER OF ANTIBODIES AND CELLS

CYTEA BIO is a Swiss/French pre-clinical stage biotech company dedicated to developing therapeutic antibody- effector cell constructs using its patented Pin™ Platform.

Our innovative approach combines Fc-engineered targeting ligands with genetically unmodified effector cells, enabling precise targeting, potentially enhancing treatment efficacy while reducing toxicity.

3+

Product candidates in pre-clinical development

6+

Years of academic research behind the platform

Potential combinations

our pin™ platform

CYTEA BIO is a preclinical-stage biotechnology company specializing in innovative ligand-driven immunotherapies that leverage unmodified allogeneic cells as effector entities. The company has developed and patented a versatile and modular therapeutic platform known as the Pin™ Platform.

pipeline

Lead program in EGFR+ glioblastoma

STRONG CYTOTOXICITY

Robust pre-clinical data demonstrate strong cytotoxicity against target cells, highly potent inhibition of tumor growth, and excellent tolerability with no observed toxicity in animal models

STRONG ARMING

Pre-arming of effector cells with Pin™ Platform transforms the ability of therapeutic cells to locate and engage targets, resulting in dramatically superior loading and efficiency of targeting ligands.

Modular approach

The versatility of the Pin™ Platform allows for customization to accommodate diverse tumor phenotypes, with rapid modifications of effector cells or ligands

Cytea Bio: Empowering effector cells

Our patented Pin™ Platform combines Fc-engineered targeting ligands with genetically unmodified allogeneic effector cells, allowing for precise targeting thus potentially improving treatment efficacy and reducing toxicity. Our key innovation involves modifying the Fc portion of ligands to significantly enhance their affinity for the CD16 receptor on effector cells. This modification enables the pre-arming of effector cells before patient administration.

Our approach stands out with its unique advantages, including enhanced potency, achieved through pre-arming cells for precise target-specific action, ensuring efficacy independent of patients’ immune system variability.

“Our patented Pin™ Platform enables practically limitless combinations of effector mechanisms and targeting ligands, building new and innovative therapies without need for drug discovery, with unrivalled efficacy, safety and economics.”

Alan Cookson

CEO of CYTEA BIO